The Importance of Use of Genetics to Guide Hypertension Therapy

Using β-Blockade as an Example
Published:September 01, 2021DOI:https://doi.org/10.1016/j.yamp.2021.06.005
      Hypertension control rates are poor, even in patients who take their medication as prescribed.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Advances in Molecular Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
        J Am Med Assoc. 2003; 289: 2560-2572
        • Forouzanfar M.H.
        • Liu P.
        • Roth G.A.
        • et al.
        Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm hg, 1990-2015.
        J Am Med Assoc. 2017; 317: 165-182
        • Kearney P.M.
        • Whelton M.
        • Reynolds K.
        • et al.
        Global burden of hypertension: analysis of worldwide data.
        Lancet. 2005; 365: 217-223
        • Muntner P.
        • Hardy S.T.
        • Fine L.J.
        • et al.
        Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018.
        J Am Med Assoc. 2020; 324: 1190-1200
        • Jarari N.
        • Rao N.
        • Peela J.R.
        • et al.
        A review on prescribing patterns of antihypertensive drugs.
        Clin Hypertens. 2015; 22: 7
        • Whelton P.K.
        • Carey R.M.
        • AronowWS
        • et al.
        2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Hypertension. 2018; 71: e13-e115
        • Schwartz G.L.
        • Turner S.T.
        • Sing C.F.
        Twenty-four-hour blood pressure profiles in normotensive sons of hypertensive parents.
        Hypertension. 1992; 20: 834-840
        • Kupper N.
        • Willemsen G.
        • Riese H.
        • et al.
        Heritability of daytime ambulatory blood pressure in an extended twin design.
        Hypertension. 2005; 45: 80-85
        • Snieder H.
        • Hayward C.S.
        • Perks U.
        • et al.
        Heritability of central systolic pressure augmentation: a twin study.
        Hypertension. 2000; 35: 574-579
        • Gong Y.
        • McDonough C.W.
        • Wang Z.
        • et al.
        Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
        Circ Cardiovasc Genet. 2012; 5: 686-691
        • Gong Y.
        • Wang Z.
        • Beitelshees A.L.
        • et al.
        Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to beta-Blockers in Hypertensive African Americans.
        Hypertension. 2016; 67: 556-563
        • Johnson J.A.
        • Turner S.T.
        Hypertension pharmacogenomics: current status and future directions.
        Curr Opin Mol Ther. 2005; 7: 218-225
        • Johnson J.A.
        • Zineh I.
        • Puckett B.J.
        • et al.
        Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
        Clin Pharmacol Ther. 2003; 74: 44-52
        • Turner S.T.
        • Schwartz G.L.
        • Boerwinkle E.
        Personalized medicine for high blood pressure.
        Hypertension. 2007; 50: 1-5
        • Turner S.T.
        • Schwartz G.L.
        • Chapman A.B.
        • et al.
        WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic.
        Hypertension. 2005; 46: 758-765
        • Evangelou E.
        • Warren H.R.
        • Mosen-Ansorena D.
        • et al.
        Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.
        Nat Genet. 2018; 50: 1412-1425
        • Chapman A.B.
        • Schwartz G.L.
        • Boerwinkle E.
        • et al.
        Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension.
        Kidney Int. 2002; 61: 1047-1055
        • Smith S.M.
        • et al.
        Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.
        Am J Hypertens. 2012; 25: 359-365
        • Neaton J.D.
        • Gong Y.
        • Turner S.T.
        • et al.
        Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
        J Am Med Assoc. 1993; 270: 713-724
        • Hiltunen T.P.
        • Donner K.M.
        • Sarin A.P.
        • et al.
        Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs.
        J Am Heart Assoc. 2015; 4: e001521
        • van der Wardt V.
        • Harrison J.K.
        • Welsh T.
        • et al.
        Withdrawal of antihypertensive medication: a systematic review.
        J Hypertens. 2017; 35: 1742-1749
        • Onesti G.
        • Schwartz A.B.
        • Kim K.E.
        • et al.
        Antihypertensive effect of clonidine.
        Circ Res. 1971; 28: 53-69
        • Materson B.J.
        • Reda D.J.
        • Cushman W.C.
        • et al.
        Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
        N Engl J Med. 1993; 328: 914-921
        • Dickerson J.E.
        • Hingorani A.D.
        • Ashby M.J.
        • et al.
        Optimisation of antihypertensive treatment by crossover rotation of four major classes.
        Lancet. 1999; 353: 2008-2013
        • Benetos A.
        • Labat C.
        • Rossignol P.
        • et al.
        Treatment With Multiple Blood Pressure Medications, Achieved Blood Pressure, and Mortality in Older Nursing Home Residents: The PARTAGE Study.
        JAMA Intern Med. 2015; 175: 989-995
        • Gupta P.
        • Patel P.
        • Strauch B.
        • et al.
        Risk Factors for Nonadherence to Antihypertensive Treatment.
        Hypertension. 2017; 69: 1113-1120
        • Wu J.
        • Kraja A.T.
        • Oberman A.
        • et al.
        A summary of the effects of antihypertensive medications on measured blood pressure.
        Am J Hypertens. 2005; 18: 935-942
        • Lefkowitz R.J.
        • Rockman H.A.
        • Koch W.J.
        Catecholamines, cardiac beta-adrenergic receptors, and heart failure.
        Circulation. 2000; 101: 1634-1637
        • Friedman D.B.
        • Musch T.I.
        • Williams R.S.
        • et al.
        Beta adrenergic blockade with propranolol and atenolol in the exercising dog: evidence for beta 2 adrenoceptors in the sinoatrial node.
        Cardiovasc Res. 1987; 21: 124-129
        • Rodefeld M.D.
        • Beau S.L.
        • Schuessler R.B.
        • et al.
        Beta-adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: identification of a high beta 2-adrenergic receptor density.
        J Cardiovasc Electrophysiol. 1996; 7: 1039-1049
        • Bristow M.R.
        • Hershberger R.E.
        • Port J.D.
        • et al.
        Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.
        Mol Pharmacol. 1989; 35: 295-303
        • Brodde O.E.
        Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure.
        Pharmacol Rev. 1991; 43: 203-242
        • Bernstein D.
        Cardiovascular and Metabolic Alterations in Mice Lacking [beta]1- and [beta]2-Adrenergic Receptors.
        Trends Cardiovasc Med. 2002; 12: 287-294
        • Dorn 2nd, G.W.
        • Tepe N.M.
        • Lorenz J.N.
        • et al.
        Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice.
        Proc Natl Acad Sci U S A. 1999; 96: 6400-6405
        • Tevaearai H.T.
        • Eckhart A.D.
        • Walton G.B.
        • et al.
        Myocardial gene transfer and overexpression of beta2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts.
        Circulation. 2002; 106: 124-129
        • Kopp U.
        • Aurell M.
        • Nilsson I.M.
        • et al.
        The role of beta-1-adrenoceptors in the renin release response to graded renal sympathetic nerve stimulation.
        Pflugers Arch. 1980; 387: 107-113
        • James P.A.
        • Oparil S.
        • Carter B.L.
        • et al.
        2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
        J Am Med Assoc. 2014; 311: 507-520
        • Zhang Y.
        • Sun N.
        • Jiang X.
        • et al.
        Comparative efficacy of beta-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis.
        J Am Soc Hypertens. 2017; 11: 394-401
        • Larochelle P.
        • Tobe S.W.
        • Lacourciere Y.
        beta-Blockers in hypertension: studies and meta-analyses over the years.
        Can J Cardiol. 2014; 30: S16-S22
        • Pepine C.J.
        • Handberg E.M.
        • Cooper-DeHoff R.M.
        • et al.
        A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
        J Am Med Assoc. 2003; 290: 2805-2816
        • Bangalore S.
        • Gong Y.
        • Cooper-DeHoff R.M.
        • et al.
        2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study.
        J Am Coll Cardiol. 2014; 64: 784-793
        • Liggett S.B.
        • Mialet-Perez J.
        • Thaneemit-Chen S.
        • et al.
        A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.
        Proc Natl Acad Sci U S A. 2006; 103: 11288-11293
        • Small K.M.
        • Brown K.M.
        • Seman C.A.
        • et al.
        Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression.
        Proc Natl Acad Sci U S A. 2006; 103: 5472-5477
        • Liu Z.
        • Barnes S.A.
        • Sokolnicki L.A.
        • et al.
        Beta-2 adrenergic receptor polymorphisms and the forearm blood flow response to mental stress.
        Clin Auton Res. 2006; 16: 105-112
        • Green S.A.
        • Cole A.G.
        • Jacinto M.
        • et al.
        A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor.
        J Biol Chem. 1993; 268: 23116-23121
        • Green S.A.
        • Turki J.
        • InnisM
        • et al.
        Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.
        Biochemistry. 1994; 33: 9414-9419
        • Green S.A.
        • Turki J.
        • Hall I.P.
        • et al.
        Implications of genetic variability of human beta 2-adrenergic receptor structure.
        Pulm Pharmacol. 1995; 8: 1-10
        • Taylor D.R.
        • Kennedy M.A.
        Genetic variation of the beta(2)-adrenoceptor: its functional and clinical importance in bronchial asthma.
        Am J Pharmacogenomics. 2001; 1: 165-174
        • Bray M.S.
        • Krushkal J.
        • Li L.
        • et al.
        Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension.
        Circulation. 2000; 101: 2877-2882
        • Drysdale C.M.
        • McGraw D.W.
        • Stack C.B.
        • et al.
        Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness.
        Proc Natl Acad Sci U S A. 2000; 97: 10483-10488
        • Snyder E.M.
        • Beck K.C.
        • Dietz N.M.
        • et al.
        Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans.
        J Physiol. 2006; 571: 121-130
        • Wolk R.
        • Snyder E.M.
        • Somers V.K.
        • et al.
        Arginine 16 glycine beta2-adrenoceptor polymorphism and cardiovascular structure and function in patients with heart failure.
        J Am Soc Echocardiogr. 2007; 20: 290-297
        • Lanfear D.E.
        • Jones P.G.
        • Marsh S.
        • et al.
        Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.
        J Am Med Assoc. 2005; 294: 1526-1533
        • Snyder E.M.
        • Johnson B.D.
        Beta2-adrenergic receptor genotype and survival after acute coronary syndrome.
        J Am Med Assoc. 2006; 295 (author reply 757-8): 756-757
        • Snyder E.M.
        • Turner S.T.
        • Joyner M.J.
        • et al.
        The Arg16Gly polymorphism of the beta2-adrenergic receptor and the natriuretic response to rapid saline infusion in humans.
        J Physiol. 2006; 574: 947-954
        • Eisenach J.H.
        • Schroeder D.R.
        • Pike T.L.
        • et al.
        Dietary sodium restriction and beta2-adrenergic receptor polymorphism modulate cardiovascular function in humans.
        J Physiol. 2006; 574: 955-965
        • Pacanowski M.A.
        • Gong Y.
        • Cooper-Dehoff R.M.
        • et al.
        beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.
        Clin Pharmacol Ther. 2008; 84: 715-721
        • Magvanjav O.
        • McDonough C.W.
        • Gong Y.
        • et al.
        Pharmacogenetic Associations of beta1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes).
        Stroke. 2017; 48: 1337-1343
        • Psaty B.M.
        • Smith N.L.
        • Heckbert S.R.
        • et al.
        Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension.
        J Am Med Assoc. 2002; 287: 1680-1689
        • Gu Q.
        • Burt V.L.
        • Dillon C.F.
        • et al.
        Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010.
        Circulation. 2012; 126: 2105-2114
        • Morawski K.
        • Ghazinouri R.
        • Krumme A.
        • et al.
        Association of a Smartphone Application With Medication Adherence and Blood Pressure Control: The MedISAFE-BP Randomized Clinical Trial.
        JAMA Intern Med. 2018; 178: 802-809
        • McManus R.J.
        • Little P.
        • Stuart B.
        • et al.
        Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial.
        BMJ. 2021; 372: m4858